Papillary thyroid carcinoma could be a rare cause of malignant pleural effusion. The development of malignant pleural effusion in patients with papillary thyroid cancer is an extremely adverse prognostic indicator. Here, we report four cases that showed development of malignant pleural effusion during the clinical course of the papillary thyroid carcinoma and consider the prognosis. In four patients, the median survival time after the development of malignant pleural effusion was only 17 months. (Endocrinol Metab 26:330-334, 2011) 
INTRODUCTION
Malignant pleural effusion usually occurs in patients with primary lung cancer, breast cancer or with malignant lymphoma. Median survival after diagnosis in those cancers had been reported to be from 3 to 12 months [1, 2] . Metastatic papillary thyroid carcinoma (PTC) could be a rare cause of malignant pleural effusion. The overall survival rate of patients with PTC at 10 years approaches 80 to 95 percent with standard treatment [3] but, the development of malignant pleural effusion is known as an adverse prognostic indicator in those patients [4] . Although a few cases of malignant pleural effusion from PTC had been reported, neither the prognosis nor the clinical courses of them has been well described in the literature [4] [5] [6] [7] [8] [9] [10] . We report here 4 cases which showed malignant pleural effusion caused by metastatic PTC and describe their clinical courses. CT of chest showed worsening of lung metastasis with newly developed multiple pleural nodules which suspected as metastatic PTC (Fig. 3) . One large pleural nodule was close to thoracic vertebrae body, so he underwent prophylactic radiation therapy to pleural nodules (15 fractions, 4,500 cGy).
CASE REPORTS
After that, brain, kidney, liver and multiple bone metastases are 
DISCUSSION
PTC is generally known as having a favorable prognosis. But, some undergo frequent recurrence and eventually die from disease progression. It is important to identify the high risk patients early and treat correctly [8] .
Fig. 3. Computed tomography of chest (patient 3).
A. Large amount of right pleural fluid, multiple pleural and lung nodules were noted. B. There was 4 cm right paravertebral mass with internal hemorrhage and it was also regarded as pleural metastatic nodule. The patient underwent prophylactic radiation therapy to the mass.
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In this report, 3 patients (patient 2, 3, and 4 in Table 1 ) were over 50 years and had cervical lymphadenopathy, extrathyroidal invasion at the time of initial surgery. Moreover, 2 patients among them (patient 3 and 4 in Table 1 ) had distant metastatic lesions at the time of initial diagnosis. They were considered as high risk group and had aggressive treatment with total thyroidectomy and radioiodine ablation therapy. But, the disease showed recurrence and progression.
In patient 1 (Table 1) , she was young at the time of diagnosis and disease was stable over 20 years. The metastatic progression appeared late but, disease progression after the appearance of pleural effusion was extremely rapid.
In retrospective report of Vassilopoulous-sellin and Sneige [8] , only 10 patients (0.6%) had malignant pleural effusion during the course of PTC among 1,772 patients. Regardless of the timing of the development of pleural effusion, the disease exhibited aggressive biologic behavior with rapid deterioration and its appearance carries an adverse prognostic significance. The median overall survival time was 27 months after the diagnosis of thyroid cancer and 11 months after the development of pleural effusion [8] . At this report, the median overall survival time after the development of malignant pleural effusion of 4 patients was also only 17 months (Table 2 ).
In reported cases so far, malignant pleural effusion resulting from metastasis of PTC had been diagnosed when cytologic examination show papillary structures of epithelial cells in pleural fluid with or without psammoma bodies [9] . In patient 3 (Table 1) , cytology noted atypical papillary clusters and pleural fluid thyroglobulin was also high as 1,610 ng/mL (serum thyroglobulin 171 ng/mL). In patient 2 (Table 1) , cytologic examination of pleural fluid could not identify the primary cancer foci due to degeneration. We checked thyroglobulin level in pleural fluid. It was 115 ng/mL which was significantly higher compared with serum thyroglobulin level (10.0 ng/ mL). We could diagnose the pleural effusion due to metastatic differentiated thyroid carcinoma based on pleural fluid thyroglobulin level. It would be the first reported case that pleural fluid of unknown cause diagnosed as malignant pleural effusion due to differentiated thyroid carcinoma by using pleural fluid thyroglobulin level.
During the course of the disease and before the diagnosis of pleural effusion, radiologically apparent lung metastasis were found in all cases in this report as well as the report of Vassilopoulous-sellin and Sneige [8] . However, Jung et al. [6] reported a patient presented with malignant pleural effusion and pleural nodules without lung metastasis and Jeong et al. [5] reported malignant pleural effusion associated with breast metastasis.
Radioiodine therapy, local radiotherapy and systemic chemotherapy could be applied for the treatment of malignant pleural effusion from PTC but, nothing was proved to be effective to control malignancy itself [8] . Intercostal tube drainage with intrapleural instillation of sclerosant was preferred to control symptom, prevent recur- PTC, papillary thyroid carcinoma.
http://www.enm-kes.org rence of effusion and recurrent aspiration [2] . In this review, all 4 patients were treated with chest tube insertion and pleurodesis.
However, patient 1 and 4 was suffered from metastatic nodule at chest tube insertion site and pleural effusion was recurred in several months in patient 1 and 2.
In conclusion, patients with PTC generally have an excellent prognosis but, high risk patients could undergo frequent recurrence and finally die of disease progression. The development of malignant pleural effusion from PTC means poor prognosis and patients with malignant pleural effusion may survive only for several months.
SUMMARY
We report 4 cases that showed development of malignant pleural effusion during the clinical course of the PTC. Pleural fluid thyroglobulin is a useful diagnostic marker when cytologic examination could not identify the origin of malignant pleural effusion. There were no effective ways to control malignant pleural effusion and the median survival time after the development of malignant pleural effusion of 4 patients was only 17 months.
